NO20025595D0 - Anvendelse av Lactobacillus casei i immunstimulerende peptider - Google Patents

Anvendelse av Lactobacillus casei i immunstimulerende peptider

Info

Publication number
NO20025595D0
NO20025595D0 NO20025595A NO20025595A NO20025595D0 NO 20025595 D0 NO20025595 D0 NO 20025595D0 NO 20025595 A NO20025595 A NO 20025595A NO 20025595 A NO20025595 A NO 20025595A NO 20025595 D0 NO20025595 D0 NO 20025595D0
Authority
NO
Norway
Prior art keywords
lactobacillus casei
immune stimulating
stimulating peptides
peptides
immune
Prior art date
Application number
NO20025595A
Other languages
English (en)
Other versions
NO332369B1 (no
NO20025595L (no
Inventor
Eric Postaire
Benjamin Bonavida
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20025595(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Publication of NO20025595D0 publication Critical patent/NO20025595D0/no
Publication of NO20025595L publication Critical patent/NO20025595L/no
Publication of NO332369B1 publication Critical patent/NO332369B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20025595A 2000-05-25 2002-11-21 Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus. NO332369B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0006679A FR2809312B1 (fr) 2000-05-25 2000-05-25 Utilisation de l. casei dans des compositions immunostimulantes
PCT/FR2001/001310 WO2001089541A1 (fr) 2000-05-25 2001-04-27 Utilisation de lactobacillus casei dans des peptides immunostimulantes

Publications (3)

Publication Number Publication Date
NO20025595D0 true NO20025595D0 (no) 2002-11-21
NO20025595L NO20025595L (no) 2003-01-22
NO332369B1 NO332369B1 (no) 2012-09-03

Family

ID=8850597

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025595A NO332369B1 (no) 2000-05-25 2002-11-21 Anvendelse av Lactobacillus casei stammen CNCM I-1518 for fremstilling av et preparat for a forsterke en spesifikk systemisk immunrespons mot et influensa-virus.

Country Status (28)

Country Link
US (1) US7604809B2 (no)
EP (1) EP1283714B1 (no)
JP (1) JP2003534284A (no)
CN (1) CN1194707C (no)
AR (1) AR028626A1 (no)
AT (1) ATE332143T1 (no)
AU (2) AU5643501A (no)
BG (1) BG65884B1 (no)
BR (1) BR0111135A (no)
CA (1) CA2410350C (no)
CZ (1) CZ303600B6 (no)
DE (1) DE60121327T2 (no)
DK (1) DK1283714T3 (no)
EA (1) EA005081B1 (no)
ES (1) ES2267763T3 (no)
FR (1) FR2809312B1 (no)
HK (1) HK1055898A1 (no)
HR (1) HRP20020935A2 (no)
HU (1) HUP0302041A3 (no)
IL (1) IL152980A0 (no)
MA (1) MA25760A1 (no)
MX (1) MXPA02011636A (no)
NO (1) NO332369B1 (no)
PL (1) PL201801B1 (no)
PT (1) PT1283714E (no)
SK (1) SK18272002A3 (no)
WO (1) WO2001089541A1 (no)
ZA (1) ZA200209087B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
GB0009294D0 (en) 2000-04-15 2000-05-31 Sec Dep For The Home Departmen Improvements in and relating to analysis of DNA samples
US9610347B2 (en) * 2001-04-30 2017-04-04 Cortcontrol Vaccination response for immunodeficiency or high cortisol
CN1317385C (zh) * 2003-05-30 2007-05-23 上海光明乳业股份有限公司 干酪乳杆菌Bd－II菌株及其在降低血脂方面的应用
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
ATE361101T1 (de) * 2004-08-24 2007-05-15 Nutricia Nv Nahrungszusammensetzung die unverdauliche oligosaccharide enthält
ZA200705844B (en) * 2004-12-15 2008-09-25 Van Der Westhuzen Corne Floris Detoxifying and immunity-booster composition
EP1683425A1 (en) * 2005-01-21 2006-07-26 Compagnie Gervais Danone Use of a fermented milk containing L. Casei for the manufacture of a composition for the prevention or treatment of a delayed-type hypersensitivity reaction
ES2264368B1 (es) * 2005-02-11 2007-12-01 Francisco Exposito Mesa Complemento alimenticio o dietetico compuesto por productos procedentes del lisado de microorganismos.
AU2006253007B2 (en) 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
BRPI0716997B8 (pt) 2006-09-10 2021-05-25 Glycotope Gmbh proteína ou composição de moléculas de proteína, métodos para produção e uso da mesma
FR2912657B1 (fr) * 2007-02-16 2009-04-17 Gervais Danone Sa Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
WO2009021585A1 (en) * 2007-08-13 2009-02-19 Dsm Ip Assets B.V. Probiotic bacteria for rducing the occurence of symptoms of winter infections
WO2009067000A1 (en) * 2007-11-20 2009-05-28 N.V. Nutricia Composition with synbiotics
EP2119365B1 (de) 2008-05-13 2017-08-16 Glycotope GmbH Fermentationsprozess
US8741365B2 (en) * 2008-05-13 2014-06-03 Glycotope Gmbh Fermentation process
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
EP2153837A1 (en) * 2008-08-14 2010-02-17 Compagnie Gervais Danone Compositions comprising Lactobacillus casei for improving resistance to common infectious diseases
FR2937252B1 (fr) * 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
WO2011083354A1 (en) * 2010-01-08 2011-07-14 Compagnie Gervais Danone Lactobacilli with anti-oxidant action
US20130121976A1 (en) * 2010-03-12 2013-05-16 Agusti Montserrat Carreras Lactic Acid Bacteria for Coeliac Disease
CN105288616B (zh) * 2010-10-15 2018-10-19 科.汉森有限公司 免疫佐剂
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
CA2844543A1 (en) 2011-08-22 2013-02-28 Glycotope Gmbh Microorganisms carrying a tumor antigen
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
CN117815404A (zh) 2018-05-18 2024-04-05 第一三共株式会社 抗-muc1抗体-药物缀合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05236872A (ja) * 1992-02-27 1993-09-17 Takanashi Nyugyo Kk 乳酸菌含有食品
JP4112021B2 (ja) * 1994-02-16 2008-07-02 明治乳業株式会社 乳酸菌を用いた免疫賦活剤
ATE173135T1 (de) * 1995-01-02 1998-11-15 Gervais Danone Co Milchsäureferment, und ihre verwendung zur herstellung von antidiarrhöeprodrukten
ES2349669T3 (es) * 1997-08-21 2011-01-10 New Zealand Dairy Board Bacterias del ácido láctico que incrementan la inmunidad.
US6699517B2 (en) * 1997-11-28 2004-03-02 Compagnie Gervais Danone Method for preparing food products by fermenting soy milk with streptococcus thermophilus
IT1298918B1 (it) * 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
KR100324441B1 (ko) * 1999-02-08 2002-02-27 이은선 위염, 위궤양, 십이지장궤양 예방을 위한 식품

Also Published As

Publication number Publication date
HRP20020935A2 (en) 2005-02-28
NO332369B1 (no) 2012-09-03
MA25760A1 (fr) 2003-04-01
AR028626A1 (es) 2003-05-14
DK1283714T3 (da) 2006-10-30
BR0111135A (pt) 2003-04-08
WO2001089541A1 (fr) 2001-11-29
PT1283714E (pt) 2006-11-30
IL152980A0 (en) 2003-06-24
FR2809312A1 (fr) 2001-11-30
MXPA02011636A (es) 2003-05-14
HUP0302041A2 (hu) 2003-09-29
CA2410350A1 (fr) 2001-11-29
HK1055898A1 (en) 2004-01-30
EP1283714A1 (fr) 2003-02-19
ES2267763T3 (es) 2007-03-16
CN1194707C (zh) 2005-03-30
CN1430518A (zh) 2003-07-16
CZ303600B6 (cs) 2013-01-02
BG107299A (bg) 2003-07-31
AU2001256435B2 (en) 2006-06-29
BG65884B1 (bg) 2010-04-30
EP1283714B1 (fr) 2006-07-05
HUP0302041A3 (en) 2005-11-28
NO20025595L (no) 2003-01-22
DE60121327D1 (de) 2006-08-17
AU5643501A (en) 2001-12-03
PL358408A1 (en) 2004-08-09
PL201801B1 (pl) 2009-05-29
EA200201248A1 (ru) 2003-06-26
FR2809312B1 (fr) 2002-07-12
US20040029127A1 (en) 2004-02-12
CZ20024189A3 (cs) 2003-05-14
CA2410350C (fr) 2013-04-09
EA005081B1 (ru) 2004-10-28
JP2003534284A (ja) 2003-11-18
ATE332143T1 (de) 2006-07-15
DE60121327T2 (de) 2007-07-26
ZA200209087B (en) 2004-06-30
SK18272002A3 (sk) 2003-08-05
US7604809B2 (en) 2009-10-20

Similar Documents

Publication Publication Date Title
NO20025595L (no) Anvendelse av Lactobacillus casei i immunstimulerende peptider
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
AU7616001A (en) Probiotic recolonisation therapy
AU1166502A (en) Human ect2 and methods of use
IS2620B (is) Mennskgerð mótefni sem greina beta-amýlóíðpeptíð
AU2001256435A1 (en) Use of lactobacillus casei in immunostimulatory compositions
NO20025657D0 (no) Anvendelse av Baculovirus-vektorer i genterapi
AU2872202A (en) Expression vectors able to elicit improved immune response and methods of using same
NO20031525D0 (no) Kjemokinmutanter i behandlingen av multippel sklerose
IL190490A0 (en) Enantiomerically pure cyclic ketones and their use in the synthesis of amino acids
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
HUP0500995A2 (en) Casein derived peptides and uses thereof in therapy
IL150679A0 (en) Use of mia in immunotherapy
HK1049353A1 (zh) 編碼環狀脂肽酰基轉移酶的基因及其表達
EP1618124A4 (en) PROPHYLACTIC AND THERAPEUTIC ADVANTAGES OF AN IMMUNE STIMULATION PEPTIDE CLASS
NO20030762L (no) Forbedret spesifisitet i behandling av sykdommer
GB0017028D0 (en) Peptides and their therapeutic use
DE60110503D1 (de) Immunostimulierende Zusammensetzung enthaltend Peptid und Hyaluronsäure
EP1578363A4 (en) NOVEL REGIONS ACCESSIBLE TO MEDICAMENTS IN SET DOMAIN PROTEINS AND METHODS OF USE
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
TW461318U (en) Improved structure of massaging chair
AU2002302618A1 (en) 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
PL336946A1 (en) Rehabilitation mattress made of wood and sponge
GB0002559D0 (en) Virulencegene and protein and their use
GB0002557D0 (en) Virulence gene and protein and their use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees